Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Evolus Inc (EOLS)

Evolus Inc (EOLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 674,468
  • Shares Outstanding, K 57,944
  • Annual Sales, $ 202,090 K
  • Annual Income, $ -61,690 K
  • 60-Month Beta 1.45
  • Price/Sales 3.46
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EOLS with:

Options Overview Details

View History
  • Implied Volatility 73.52% ( +1.69%)
  • Historical Volatility 29.40%
  • IV Percentile 86%
  • IV Rank 52.18%
  • IV High 123.43% on 10/24/23
  • IV Low 19.05% on 02/05/24
  • Put/Call Vol Ratio 0.31
  • Today's Volume 51
  • Volume Avg (30-Day) 272
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 11,225
  • Open Int (30-Day) 17,898

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.16
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.26 +2.66%
on 04/18/24
14.37 -19.55%
on 03/21/24
-2.44 (-17.43%)
since 03/18/24
3-Month
11.26 +2.66%
on 04/18/24
15.43 -25.09%
on 03/04/24
-0.28 (-2.36%)
since 01/18/24
52-Week
7.07 +63.51%
on 07/06/23
15.43 -25.09%
on 03/04/24
+3.40 (+41.67%)
since 04/18/23

Most Recent Stories

More News
Why Shares of Evolus Are Jumping Thursday

The stock climbed on record second-quarter revenue and a raise in full-year guidance.

EOLS : 11.56 (-0.69%)
Twitter Faces Threats From AI and Threads

AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience.

META : 501.80 (+1.54%)
GOOGL : 156.01 (+0.35%)
ADBE : 473.18 (-0.27%)
GOOG : 157.46 (+0.37%)
EOLS : 11.56 (-0.69%)
DIS : 112.43 (-0.45%)
PM : 91.20 (+0.68%)
MODG : 15.41 (-1.66%)
GOLF : 61.42 (-0.11%)
TWTR : 53.70 (+0.66%)
WMT : 59.26 (-0.65%)
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EOLS : 11.56 (-0.69%)
AYRWF : 2.4700 (-9.74%)
Evolus to Report First Quarter 2023 Results and Provide Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial...

EOLS : 11.56 (-0.69%)
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BIO : 281.02 (-3.38%)
EOLS : 11.56 (-0.69%)
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

OrganiGram (OGI) delivered earnings and revenue surprises of -100% and 9.74%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

OGI : 1.8700 (+2.19%)
EOLS : 11.56 (-0.69%)
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

EOLS : 11.56 (-0.69%)
MGNX : 16.07 (-0.19%)
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the fourth quarter and full...

EOLS : 11.56 (-0.69%)
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TGTX : 13.99 (+1.23%)
EOLS : 11.56 (-0.69%)
Evolus to Participate in the Barclays Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating...

EOLS : 11.56 (-0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

3rd Resistance Point 12.18
2nd Resistance Point 11.93
1st Resistance Point 11.75
Last Price 11.56
1st Support Level 11.32
2nd Support Level 11.07
3rd Support Level 10.89

See More

52-Week High 15.43
Fibonacci 61.8% 12.24
Last Price 11.56
Fibonacci 50% 11.25
Fibonacci 38.2% 10.26
52-Week Low 7.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar